117 completed, 11 unknown, 4 recruiting, 3 active not recruiting. 144 Phase 3, 11 Phase 2.
Follow Sebaceous Gland Diseases: new trials by email Literature Review of Sebaceous Gland Diseases trials Research Report on Sebaceous Gland Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) Denifanstat, Placebo - Acne Vulgaris | Phase 3 | Recruiting | Sagimet Biosciences Inc. | 800 | 2026-10-01 | 2026-10-29 |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 309 | 2026-08-24 | 2026-08-21 |
| Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg), Placebo - Acne Vulgaris, Acne Vulgaris on the Face | Phase 3 | Recruiting | Eurofarma Laboratorios S.A. | 531 | 2026-08-24 | 2026-10-27 |
| 1% Clascoterone Cream for the Treatment Acne Vulgaris 1% Clascoterone Cream, Placebo - Acne Vulgaris | Phase 3 | Not yet recruiting | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 692 | 2026-05-04 | 2026-03-09 |
| A Split-Face Comparative Study of Mono Threads Versus Combination With Plasma Gel for the Treatment of Post-Acne Scars polydioxanone (PDO) mono threads, Mono Threads with Plasma Gel - Acne | Phase 2 / Phase 3 | Enrolling by invitation | Tanta University | 20 | 2025-11-10 | 2026-10-29 |
| A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Trifarotene, Vehicle Cream - Acne Vulgaris | Phase 3 | Active not recruiting | Galderma R&D | 561 | 2025-09-23 | 2026-08-24 |
| Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients ISOtretinoin 5 MG, Topical cream - Acne Vulgaris | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nice | 420 | 2025-04-29 | 2026-10-01 |
| The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol Cleanser, Combination cream, spot cream - Acne Vulgaris | Phase 3 | Not yet recruiting | Dr.dr.Irma Bernadette, SpKK (K) | 102 | 2025-03-01 | 2025-01-16 |
| A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT) N-Acetyl-GED-0507-34-LEVO gel 5% - Acne Vulgaris | Phase 3 | Active not recruiting | PPM Services S.A. | 400 | 2024-12-05 | 2026-09-15 |
| A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5% in Patients With Acne Vulgaris (GEDACNE 2) N-Acetyl-GED-0507-34-Levo, N-Acetyl-GED-0507-34-Levo corresponding vehicle - Acne Vulgaris | Phase 3 | Completed | PPM Services S.A. | 398 | 2024-11-19 | 2026-09-15 |
| A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Patients With Acne Vulgaris (GEDACNE-1) N-Acetyl-GED-0507-34-Levo 5% gel, N-Acetyl-GED-0507-34-Levo corresponding vehicle - Acne Vulgaris | Phase 3 | Completed | PPM Services S.A. | 407 | 2024-11-19 | 2026-09-15 |
| Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome tretinoin 0.025% + Z. officinale patch, tretinoin 0.025% cream - Acne Vulgaris | Phase 2 / Phase 3 | Active not recruiting | Hasanuddin University | 26 | 2024-11-03 | 2025-09-15 |
| A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks. Dermapen 4™ - Acne | Phase 2 / Phase 3 | Unknown | Equipmed USA LLC | 10 | 2024-10-01 | 2024-09-19 |
| Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast Montelukast 10 Mg Oral Tablet - Acne Vulgaris | Phase 3 | Unknown | South Valley University | 60 | 2024-06-01 | 2024-04-03 |
| Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris Clascoterone, Vehicle cream - Acne Vulgaris | Phase 3 | Recruiting | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 692 | 2024-05-20 | 2025-07-09 |
| A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris ASC40 - Acne | Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 240 | 2024-04-18 | 2025-12-01 |
| Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris ISOtretinoin 20 MG - Acne Vulgaris | Phase 3 | Completed | Mostafa Bahaa | 40 | 2024-01-30 | 2025-03-04 |
| A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris ASC40 - Acne | Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 480 | 2024-01-23 | 2025-06-19 |
| DMT310-009 Topical in the Treatment of Acne Vulgaris DMT310, Placebo - Acne Vulgaris | Phase 3 | Completed | Dermata Therapeutics | 520 | 2023-12-08 | 2025-08-22 |
| Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo - Acne Vulgaris | Phase 3 | Completed | Teva Pharmaceuticals USA | 807 | 2022-09-19 | 2024-09-26 |
Showing 20 of 144. Sign in to see all of them.
Acne Vulgaris (137) · Dermatitis, Seborrheic (7) · Furunculosis (3) · Hidradenitis Suppurativa (3) · Psoriasis (3) · Abscess (1) · Dandruff (1) · Dermatitis, Atopic (1) · Dermatitis, Contact (1) · Facies (1) · Hyperpigmentation (1) · Inflammation (1)
Skin Diseases (144) · Skin and Connective Tissue Diseases (144) · Acneiform Eruptions (137) · Skin Diseases, Papulosquamous (9) · Dermatitis (7) · Skin Diseases, Eczematous (7) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Infections (4) · Skin Diseases, Bacterial (4) · Skin Diseases, Infectious (4) · Animal Diseases (3) · Fish Diseases (3) · Gram-Positive Bacterial Infections (3)
Gels (16) · Adapalene (13) · Benzoyl Peroxide (13) · Clindamycin (10) · trifarotene (6) · Adapalene, Benzoyl Peroxide Drug Combination (5) · Minocycline (5) · Tretinoin (5) · Clascoterone (4) · Doxycycline (4) · Isotretinoin (4) · drospirenone and ethinyl estradiol combination (4) · tazarotene (4) · Adalimumab (3) · berdazimer sodium (3)
Galderma R&D (20) · Bausch Health Americas, Inc. (9) · Almirall, S.A. (5) · Padagis LLC (5) · Stiefel, a GSK Company (5) · Bayer (4) · AbbVie (prior sponsor, Abbott) (3) · Actavis Inc. (3) · Cassiopea SpA (3) · Dermira, Inc. (3) · GlaxoSmithKline (3) · Novan, Inc. (3) · PPM Services S.A. (3) · Spear Pharmaceuticals (3) · Vyne Therapeutics Inc. (3)
United States (83) · Canada (26) · Belize (10) · China (9) · Poland (9) · Brazil (5) · Italy (5) · Australia (4) · France (4) · Germany (4) · Hungary (4) · Japan (4) · Spain (4) · Ukraine (4) · Czechia (3)
Anya Loncaric (6) · Beth Zib (3) · David Berk, MD (3) · Michael Graeber, MD (3) · Anya Loncaric, MS (2) · Jerry Tan, MD (2) · Joyce Rico, MD (2) · Kevin Chan (2) · Tim Theisen (2) · Abdulrahman Abdul Hamid Alsaied, Professor (1)
PMID 27518661, PMID 27847545, PMID 29380251, PMID 30500139, PMID 30500140, PMID 30500141, PMID 32320027, PMID 32886337, PMID 34607697, PMID 36745367, PMID 38724841, PMID 39141589, PMID 40377868, PMID 18720689, PMID 18827119, PMID 19746769, PMID 21288628, PMID 23547851, PMID 24934963, PMID 26293170, PMID 26945741, PMID 27075705, PMID 28686775, PMID 28686776, PMID 31251543, PMID 32038757, PMID 32108322, PMID 32586344, PMID 36933926, PMID 38206145, PMID 38380975, PMID 39487326
2023 (3), 2014 (1), R01AR053542 (1)